CerFlux, Inc.
CerFlux is a Birmingham-based cancer biotech company dedicated to creating advanced, personalized medicine solutions. Their innovative technologies include the patented ChipMux® biopsy-on-a-chip for testing multiple anticancer agents directly on tumor biopsy tissue, aiming to improve cancer treatment outcomes through rapid, personalized, and effective therapies. The company actively participates in industry events, receives grants and awards, and collaborates with research institutions to advance cancer research and personalized medicine.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Microchamber array multiplexer device for biopsy testing
Chip-based microchamber array device designed to expose a single intact tumor biopsy to multiple fluids/therapeutic agents concurrently while preserving tissue microarchitecture and enabling multiplexed efficacy assessment.
Microchamber array multiplexer device for biopsy testing
Chip-based microchamber array device designed to expose a single intact tumor biopsy to multiple fluids/therapeutic agents concurrently while preserving tissue microarchitecture and enabling multiplexed efficacy assessment.
Services
Laboratory service that screens multiple approved or experimental therapeutic regimens concurrently on a patient’s biopsy tissue to identify likely effective and ineffective options prior to clinical treatment.
Research service to evaluate panels of preclinical candidate molecules or formulations on patient-derived tumor tissue or organoid surrogates to estimate clinical relevance and prioritize assets for development.
Advisory and data-analytics services to integrate ex vivo assay outputs with machine learning models to produce individualized efficacy scores and support translational decision-making and trial design.
In-house prototyping and small-batch fabrication services including microfabrication and 3D printing for device development, auxiliary products, and rapid-response production of PPE or device adaptors.
Laboratory service that screens multiple approved or experimental therapeutic regimens concurrently on a patient’s biopsy tissue to identify likely effective and ineffective options prior to clinical treatment.
Research service to evaluate panels of preclinical candidate molecules or formulations on patient-derived tumor tissue or organoid surrogates to estimate clinical relevance and prioritize assets for development.
Advisory and data-analytics services to integrate ex vivo assay outputs with machine learning models to produce individualized efficacy scores and support translational decision-making and trial design.
In-house prototyping and small-batch fabrication services including microfabrication and 3D printing for device development, auxiliary products, and rapid-response production of PPE or device adaptors.
Expertise Areas
- Personalized oncology diagnostics
- Ex vivo tumor modeling and multiplexed testing
- Microfluidics and microchamber array development
- Translational research partnerships and analytics
Key Technologies
- Microfluidic microchamber arrays
- Ex vivo core-biopsy testing workflows
- High-content fluorescence imaging
- Custom image-processing algorithms
News & Updates
CerFlux received a grant to develop ChipMux® technology for personalized cancer treatment, supporting the transition from lab research to clinical application.
CerFlux received a competitive SBIR Phase I grant from the NSF to develop ChipMux technology for personalized cancer therapy.
Dr. Karim I. Budhwani will lead a panel discussing the future of personalized precision oncology at BIO 2025.
Dr. Karim Budhwani will lead a panel on AI's role in revolutionizing cancer drug discovery at BIO 2024.
CerFlux was awarded a grant to support the development of ChipMux® technology for personalized cancer treatment.
Dr. Karim I. Budhwani will lead a panel discussing the future of personalized oncology at BIO 2025.
CerFlux received a grant to develop ChipMux® technology for personalized cancer treatment, supporting the transition from lab research to clinical application.
CerFlux received a competitive SBIR Phase I grant from the NSF to develop ChipMux technology for personalized cancer therapy.
Dr. Karim I. Budhwani will lead a panel discussing the future of personalized precision oncology at BIO 2025.
Dr. Karim Budhwani will lead a panel on AI's role in revolutionizing cancer drug discovery at BIO 2024.
CerFlux was awarded a grant to support the development of ChipMux® technology for personalized cancer treatment.
Dr. Karim I. Budhwani will lead a panel discussing the future of personalized oncology at BIO 2025.